Log In
BCIQ
Print this Print this
 

RXDX-105 (formerly CEP-32496)

  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionSmall molecule inhibitor of BRAF, EGFR and RET
Molecular Target BRAF ; Epidermal growth factor receptor (EGFR)
Mechanism of ActionRET inhibitor; BRAF inhibitor; Epidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationMelanoma
Indication DetailsTreat melanoma
Regulatory Designation
PartnerIgnyta Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$40.6M

$2.3M

$27.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today